Product Details
Breast Cancer is quite possibly the most widely recognized malignancy among ladies around the world. About 20% of breast cancer malignant growths are hereditary. Around 30% of the mutations have stayed negative after testing BRCA1/2 even in families with a Mendelian inheritance pattern for breast cancer. Additionally, non-BRCA genes have been identified as inclining for breast cancer. Multigene panel testing attempts to hide and clarify the BRCA negative inherited carcinoma, further improving efficiency, speed and costs of the carcinoma screening. The test incorporates both well-established carcinoma vulnerability genes, also as candidate genes with limited proof of an association with breast cancer.